ClinicalTrials.gg
CompletedNCT00485576Updated Jan 15, 2009

Safety and Efficacy Study of Eculizumab in Patients With Mild Allergic Asthma

A Phase 2 interventional study of eculizumab in Allergic Asthma, sponsored by Alexion Pharmaceuticals, Inc.. Completed at 2 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-01-15.

Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
21
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 359 studies in Asthma by AstraZeneca — 19 open to participants now, 28 under way, 8 of them phase 3. Asthma · AstraZeneca.

Enrollment
223rd of 248
21 · median 175
Started
2007
with 17 others
Phase 2
50 of 359
2 open now
Registered
58th of 359
by date

Among the 359 studies in Asthma by AstraZeneca, this one is the 223rd largest by enrollment of the 248 interventional ones that give a count, is one of 18 that started in 2007, is one of 50 in phase 2, and was the 58th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

19 of the 359 studies in Asthma by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

14 more — sign in →

By country, each count listing its studies:

All 19 open studies →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 359 studies in Asthma by AstraZeneca, or all of them as a file.
02

Study summary

This study is to designed to test the role of complement in the late asthmatic response to allergen challenge in mild asthma, as an indicator of the possible role of complement in the broader asthmatic population.

03

Conditions studied

  • Allergic Asthma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • diagnosed with stable, mild, allergic asthma;
  • history of episodic wheeze and shortness of breath;
  • sexually active women of must use during the entire duration of study;
  • willing and able to give ;
  • positive methacholine challenge;
  • positive skin prick test to common aeroallergens;
  • positive allergen-induced early and late phase bronchoconstrictor response
  • at least 70% of predicted value;
  • PC20 at baseline that is within 1 doubling dose of that measured during screening

Exclusion criteria

Exclusion:

  • active bacterial infection;
  • respiratory tract infection or worsening of asthma within 28 days
  • use of inhaled or topical within 28 days or use of systemic corticosteroids within 90 days;
  • use of cromoglycate, nedocromil, leukotriene receptor antagonists and inhibitors of 5-lipoxygenase within 14 days;
  • use of antihistamines, immunosuppressives, or any medications that interact with eculizumab;
  • use of theophylline-containing agents (any type), long-acting beta 2-agonists (salmeterol, formoterol) or long-acting anticholinergics within 14 days;
  • use of NSAIDs prior to spirometry;
  • use of tobacco products currently or within the previous 12 months; or smoking history > 10 pack-years;
  • lung disease other than mild allergic asthma;
  • patients with LAR who have not been vaccinated against Neisseria meningitidis;
  • or infection;
  • parasitic infection;
  • participation in any other drug trial;
  • pregnant or breast feeding women, or intending to conceive during the course of trial;
  • known to the treatment drug or any of its ;
  • history of illicit drug use or alcohol abuse within previous year;
  • any abnormality on screening lab test results;
  • abnormal chest X-ray;
  • chronic use of any other medication for treatment of allergic lung disease other than short-acting beta2-agonists or ipratropium bromide;
  • any medical condition that might interfere with the subject's participation in the study or confound the assessment of the subject;
  • unwilling or inability to comply with the study protocol for any reason.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
21 participants (actual)

Interventions

  • eculizumab 600 mg or matching placebo iv infusion.

06

What researchers measure

Primary outcomes

  1. Allergen-induced late asthmatic response as measured by the AUC of FEV1 from 3 to 7 hours post-allergen challenge

    Time frame: 7 hours

Secondary outcomes

  1. At 24 hours post-allergen challenge; treatment comparison of allergen-induced changes from baseline in sputum eosinophils and metachromatic cells

    Time frame: 72 hours

  2. Allergen-induced airway responsiveness 24 hours post-allergen challenge as primary interest; 72 hour assessment timepoint will be supportive

    Time frame: 72 hours

  3. Maximum % decrease in FEV1 from 3 to 7 hours post-allergen challenge

    Time frame: 7 hours

  4. % decrease of FEV1 at 24 hours post-allergen challenge

    Time frame: 24 hours

  5. AUC and maximum % fall of FEV1 from 0-3 hours post-allergen challenge

    Time frame: 3 hours

07

Study locations

2 sites
  • McMaster University
    Hamilton, Ontario L8N 3Z5, Canada
  • Hospital Laval
    Ste-Foy, Quebec G1V 4G5, Canada
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2007, a primary completion of Sep 2008 and a completion of Nov 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 12, 2007
First posted
Jun 13, 2007
Start
Sep 2007
Primary completionActual
Sep 2008
CompletionActual
Nov 2008
Last update
Jan 15, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 15, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00485576
First posted
Jun 13, 2007
Start date
Sep 2007
Primary completion
Sep 2008
Completion
Nov 2008
Last update
Jan 15, 2009

Study contacts

Henk-Andre Kroon, MD
study director · Alexion Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eculizumab

Start the discussion